CJC-1295 + Ipamorelin: How the Stack Works and What to Track

CJC-1295 plus Ipamorelin is probably the most talked-about stack in the peptide world. Search for any “beginner protocol” and it’s there.

The logic behind it is genuinely interesting. The evidence for the specific combination is a lot thinner than the hype. Here’s the honest version: how it’s supposed to work, what the research really covers, where it stands legally in 2026, and what you’d need to track to know whether anything is happening.

Two Signals, One Gland

Your pituitary releases growth hormone in pulses, and two separate signals push it to fire.

GHRH (growth hormone-releasing hormone) tells the pituitary to release GH. CJC-1295 is a modified GHRH analog built to last much longer than the natural hormone.

Ghrelin-receptor agonists (often called GHRPs or GH secretagogues) amplify GH release through a different receptor. Ipamorelin is one of these.

“Stacking” just means hitting both pathways at once, on the theory that the combined pulse is bigger than either one alone.

What the Research Actually Shows

This is where it’s worth slowing down, because three different bodies of evidence get blended together online.

The synergy is real, in principle. Human studies have shown that GHRH and GHRP together drive markedly more GH release than either alone. In one well-designed study of 47 men, Veldhuis and Bowers (2009) found that this synergy was weaker with older age and more visceral fat. But they used GHRH and GHRP-2 infusions in a research setting, not CJC-1295 and Ipamorelin. The popular claim that the stack is “2–10x stronger” isn’t from a synergy study at all.

CJC-1295 has a small human trial. In two placebo-controlled trials in healthy adults, Teichman et al. (2006) showed CJC-1295 produced sustained, dose-dependent increases in GH and IGF-1, with no serious adverse reactions reported. That’s where the “2–10 fold” figure comes from: CJC-1295 on its own, compared against baseline. It was a pharmacology study. It didn’t measure body composition, recovery or sleep.

Ipamorelin’s selectivity comes from animals. The paper that made Ipamorelin famous, Raun et al. (1998), found it released GH in rats and pigs without raising ACTH or cortisol, unlike older GHRPs such as GHRP-6. That selectivity is the reason people prefer it. It’s also an animal finding.

So the combination rests on a sound mechanism, one short human trial of one component, and animal data on the other. Nobody has run a controlled human trial of the stack itself for the outcomes people actually want.

What People Hope to See

Users usually report better sleep first, then recovery, then body composition changes. Treat those as anecdotes. They’re hard to separate from placebo, better habits, and the simple fact that people who start a protocol often start sleeping and eating better at the same time.

It’s also worth knowing what elevated GH can do on the downside. A systematic review of GH therapy in healthy older adults found small body composition improvements but more side effects, including soft tissue swelling, joint pain and carpal tunnel syndrome. That review studied GH itself, not secretagogues, but it tells you which symptoms to take seriously.

Where It Stands Legally in 2026

Neither compound is FDA-approved. When FDA removed 12 peptides from its Category 2 list in April 2026, CJC-1295 and Ipamorelin weren’t among them, and neither was part of the July 2026 advisory committee review. The regulatory picture is moving fast, so check current guidance before assuming anything.

For athletes, it’s simple. The WADA Prohibited List bans both at all times, CJC-1295 as a GHRH analogue and Ipamorelin as a GH secretagogue.

How to Track It Like You Mean It

If you and a clinician decide this is something you want to explore, tracking is what turns “I think it’s working” into an answer. Here’s what matters.

Before you start. Two weeks of baseline data on sleep, HRV and resting heart rate. A body composition scan and photos. And a blood panel your clinician agrees on. IGF-1 is the standard marker for GH activity, since GH itself is released in pulses and a single GH blood test says little. Fasting glucose and HbA1c belong on the list too.

Every day. HRV, resting heart rate, sleep duration, and a quick rating of energy and recovery. Note the confounders: alcohol, travel, illness, hard training days.

Every log. Date, time, what you took and where. Plus anything unusual you noticed.

At checkpoints. Repeat the scan, photos and blood work at the midpoint and the end, under the same conditions as your baseline. Our guide to blood panels covers what to test and how to keep results comparable.

Pinnacle Pulse is built around this kind of log. You record each entry with optional sleep, HRV and soreness data, and your history stays searchable and exportable, so you can actually compare week two with week ten. If you’ve never set up a tracking block before, the 12-week tracking guide walks through it.

Why IGF-1 Needs Context

IGF-1 is the marker everyone watches with GH-related compounds, and it deserves some nuance.

First, there’s no single “good” number. MedlinePlus notes that a lower-than-normal IGF-1 result can simply reflect a normal age-related decrease. So your result is only meaningful against the range your lab uses for people like you and, more importantly, against your own baseline.

Second, higher isn’t automatically better. A rise in IGF-1 tells you GH signaling has gone up. It doesn’t tell you you’re recovering better or building more muscle. Those need their own measures.

Third, IGF-1 travels with other markers. The GH review mentioned above found side effects like swelling and joint pain with GH itself, and the two-year MK-677 trial in our sleep guide found higher fasting glucose and lower insulin sensitivity alongside higher IGF-1. That’s why IGF-1 should never be the only line on your panel.

A Worked Example (Illustrative)

Here’s a fictional example showing how tracking clarifies what a block did. The person and details are invented.

Tom, 45, works with a clinician who agrees to a supervised trial. Before starting, Tom collects two weeks of overnight HRV, resting heart rate and sleep from his watch, rates his energy and recovery each morning on an anchored scale, gets a body scan and photos, and has a morning fasted blood panel including IGF-1, fasting glucose and HbA1c.

Over the first weeks, Tom feels like he’s sleeping deeper. His watch’s sleep duration barely changes, though, and his morning energy scores are about the same as baseline. He notes the gap honestly.

At the midpoint, IGF-1 is up compared with baseline. Fasting glucose is slightly higher too. His clinician wants to keep an eye on it. Around the same time, Tom logs mild tingling in his fingers in the mornings and mentions it at his next check-in, rather than waiting.

At the end, his body scan shows little change. Strength is similar. His clinician weighs the higher glucose and the tingling against a modest, mostly subjective benefit, and they decide to stop.

Without the log, Tom would probably have remembered this as “it helped my sleep.” With it, he knows the objective sleep data didn’t move, two markers headed in the wrong direction, and the decision was easy to make.

Common Mistakes

Testing GH instead of IGF-1. GH comes in pulses, so a single GH reading tells you very little.

Watching IGF-1 and nothing else. Glucose, HbA1c and symptoms belong alongside it.

Treating better sleep as proof. Feeling like you sleep better is worth logging. Check it against your sleep duration and morning scores before believing it.

Ignoring early symptoms. Swelling and tingling are easy to dismiss. Log them and mention them.

Changing other things at the same time. A new training plan or diet started in the same week will muddy any result.

Assuming the vial matches the label. Gray-market purity is unknown, which limits what any result can tell you.

Questions for Your Clinician

1. Given my age and health history, is there any reason this is a bad idea for me?
2. Which blood markers should we check at baseline, and when should we recheck them?
3. Which symptoms should make me stop and call you?
4. What would count as a meaningful benefit, and how will we measure it?
5. If my glucose markers move, what’s the plan?

Red Flags Worth a Phone Call

Stop and talk to a clinician if you notice:

• Swelling in your hands, feet or face
• Tingling, numbness or wrist pain
• Persistent joint pain
• A rise in fasting glucose or HbA1c
• Anything that just feels wrong

Don’t adjust on your own based on how you feel. That’s exactly the kind of decision that needs someone looking at your labs.

One Problem Tracking Can’t Fix

Most CJC-1295 and Ipamorelin sold online comes from the gray market, where purity and content are anyone’s guess. FDA has told sellers that a “research purposes only” label doesn’t stop a peptide sold for human use from being an unapproved drug. Good data can tell you that nothing changed. It can’t tell you whether the vial contained what the label said.

That’s the real takeaway here. The mechanism is elegant, the human evidence for the stack is thin, and the product you get may not match the paper. Go in with clear eyes, a clinician, and a tracking plan. For the basics of how peptides work and how they’re regulated, start with What Are Peptides?.

This article is for educational purposes only and is not medical advice. CJC-1295 and Ipamorelin are not FDA-approved. Talk to a qualified clinician before starting, stopping or changing any compound, and check the laws where you live.

FAQ

Is CJC-1295 or Ipamorelin FDA-approved?

No. Neither is an FDA-approved drug, and neither was among the 12 peptides FDA moved off its Category 2 list in April 2026 or reviewed by its advisory committee in July 2026.

Does the GHRH plus GHRP synergy actually exist?

Yes, in human research the two signals together release more growth hormone than either alone. That work used GHRH and GHRP-2 infusions in a lab, though, not the CJC-1295 and Ipamorelin combination people buy.

Can athletes use CJC-1295 or Ipamorelin?

Not in tested sport. WADA's 2026 Prohibited List names CJC-1295 as a GHRH analogue and Ipamorelin as a growth hormone secretagogue, both banned at all times.